Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report By Drug Class (Diuretics, ACE Inhibitors), By Type (Primary, Secondary), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Anti-hypertensive Drugs Market Trends

The global anti-hypertensive drugs market size was estimated at USD 23.57 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 3.91% from 2024 to 2030.Major factors contributing to the market's growth includeincreasing prevalence of hypertension, growing geriatric population, and favorable initiatives undertaken by market players. In December 2022, Idorsia Pharmaceuticals Ltd. submitted an NDA to the U.S. FDA for its aprocitentan to manage difficult-to-treat hypertension. Similarly, in January 2023, the company submitted a market authorization application to the EMA for the treatment of resistant hypertension.

Increasing number of high blood pressure patients globally is one of the major factors driving the market growth. According to a WHO report published in March 2023, an estimated 1.28 billion people aged 30 to 79 years have hypertension, and most of these people live in low and-middle-income countries. Moreover, increased tobacco consumption, particularly in the form of smoking, is strongly associated with an increased risk of hypertension. According to Centers for Disease Control and Prevention, in 2021, approximately 28.3 million U.S. adults currently smoked cigarettes, followed by 13.1% of men and 10.1% of women.

Due to increasing risk of developing cardiovascular diseases, market players & research institutes are investing heavily to develop novel therapeutic drugs to manage high blood pressure. In July 2023, F. Hoffmann-La Roche Ltd signed a deal with Alnylam Pharmaceuticals Inc. worth around USD 2.8 billion for a potential treatment of hypertension. Similarly, in January 2023, AstraZeneca acquired CinCor Pharma, Inc., involved in developing novel treatments for hypertension and chronic kidney disease. CinCor Pharma, Inc. has baxdrostat (CIN-107) in the pipeline targeting to lowering blood pressure in treatment-resistant hypertension.

Government and non-government institutes are taking initiatives to manage and control worldwide. The Indian Ministry of Health & Family Welfare, in association with WHO and other healthcare regulatory bodies, introduced the Indian Hypertension Control Initiative (IHCI) to strengthen the country's building blocks of high blood pressure management and control. There has been a significant increase in the adoption of online retail platforms that offer antihypertensive drugs based on the required dosage, which, coupled with the growth of the pharmaceutical and e-commerce industries, is driving the growth of the market. The adoption of health insurance policies that provide financial assistance for hypertension treatment and help to reduce healthcare expenses has further propelled the market growth.

Drug Class Insights

Calcium channel blockers (CCB) segment held the largest market share of 26.23% in 2023 owing to lesser side effects exhibited by these drugs compared to other anti-hypertensive drugs. Moreover, long-acting CCBs provide more consistent blood pressure control throughout the day and require less frequent dosing. Their efficacy, safety profile, diverse options, and suitability for combination therapy make CCD a vital component of hypertension management. These factors are contributing to the large share of the market.

ACE inhibitors segment is expected to grow at the fastest CAGR of 4.96% over the forecast period.The rising prevalence of high blood pressure and increasing prescription of these drugs for cardiovascular diseases & other chronic conditions are major drivers for the segment growth. Moreover, availability of generic forms makes it a cost-effective option for hypertension management, which is anticipated to increase the prescription rate over the projected years.

Type Insights

Primary hypertension segment held the largest market share of 71.51% in 2023. It is the most common type of hypertension and accounts for majority of cases. According to the National Ambulatory Medical Care Survey 2019, in the U.S. medical records, 33.2% of patients visit physician offices due to primary hypertension. Growing number of cases of essential hypertension, driven by factors such as lifestyle choices, an aging population, improved detection, and effective treatment guidelines, contributes to the expansion of the market.

Secondary hypertension segment is expected to grow with a significant CAGR of 4.34% over the forecast period attributed to increasing prevalence of underlying medical conditions such as kidney disease & hormonal disorders, improved diagnosis of secondary hypertension, and development of new anti-hypertensive drugs. Moreover, major pharmaceutical companies are investing in developing new anti-hypertensive drugs for secondary hypertension through various strategies such as collaborations, new product launches, mergers, and acquisitions.

Route of Administration Insights

Oral segment held the largest market share of 75.40% in 2023 and is expected to grow at the fastest CAGR. This growth is attributed to increased patient preference for oral medications and growing demand for fixed-dose combinations of anti-hypertensive drugs. Pharmaceutical companies constantly develop new oral anti-hypertensive drugs with improved efficacy and safety profiles. This is also driving the growth of the market's oral route of administration segment. In  April 2021, the FDA approved Macitentan Tablets, 10 mg of Zydus Worldwide DMCC. These tablets are used to treat pulmonary arterial hypertension and reduce the risks of disease progression.

Injectables segment held the second-largest share of the market. Injectable anti-hypertensive drugs are a crucial component of the treatment in cases of hypertensive emergencies, where rapid and precise blood pressure reduction is necessary. Moreover, increasing hospitalization due to life-threatening diseases and chronic conditions, such as heart attacks, strokes, and kidney disease, is expected to increase the demand for injectable drugs.

Distribution Channel Insights

Hospital pharmacy segment accounted for the largest market share of 53.21% in 2023. This can be attributed to increase in the number of hospitalizations due to high blood pressure and other chronic diseases. Additionally, anti-hypertensive drugs are prescription-based medications prescribed by specialized healthcare professionals who are available in hospital settings, contributing to segment's growth. A doctor's prescription enables healthcare professionals to assess the patient's overall health and medication regimen to minimize risks and manage any potential side effects or drug interactions. It is expected to fuel the demand for anti-hypertensive drugs in the hospital pharmacy segment.

Online pharmacy segment is expected to grow at the fastest CAGR during the projected timeframe attributed to increasing convenience, affordability, and privacy that online pharmacies offer to patients. Moreover, government bodies are ensuring that patients have access to the medications they need to manage their hypertension. For instance, in November 2019, the National Health Service (NHS) Digital Pharmacy Program UK introduced the Electronic Prescription Service (EPS). The EPS makes it easier for patients to obtain anti-hypertensive and other drugs.

Regional Insights

North America accounted for the largest revenue share of 37.55% in 2023 owing to the availability of anti-hypertensive drugs and development of new and more effective anti-hypertensive drugs. Moreover, surge in the incidence of hypertension and rise in obesity significantly contribute to the growth of the market in the region. According to Centers for Disease Control and Prevention, obesity in the U.S. affects 100.1 million people in 2023, with adults 41.9% and 19.7% of children. These factors are contributing to the significant share of the region.

Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Increasing prevalence of hypertension in Asia Pacific region is a major driver for the market. As the population ages and lifestyles change, incidence of hypertension is rising. Excessive salt consumption is a significant contributor to the prevalence of hypertension in the Asia Pacific region. According  to the WHO, China consumes excessive salt in food, an average of 9.3 grams per day in home cooking, which is approximately double as compared to the recommended amount. More than 27.5% of Chinese adults have high blood pressure and cardiovascular disease. These factors are expected to drive the regional market growth.

Key Companies & Market Share Insights

Companies are undertaking strategic initiatives such as collaborations, geographic expansion, and strategic agreements for product portfolio expansion to maximize their market share. To sustain their presence in the market, industry players are further concentrating on acquisitions & mergers and product approval.

• In March 2023, Alembic Pharmaceuticals Limited received FDA approval for Prazosin Hydrochloride Capsule indicated for the treatment of hypertension. It is an abbreviated new drug application therapeutically equivalent to Pfizer’s Minipress Capsules of strength 1, 2, and 5 mg.

• In January 2023, AstraZeneca entered into an agreement to acquire CinCor Pharma, a company that focuses on developing treatment for uncontrolled and resistant hypertension. The acquisition aims to strengthen AstraZeneca’s pipeline.

Anti-hypertensive Drugs Market Report Scope

Global Anti-hypertensive Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anti-hypertensive drugs market report based on drug class, type, route of administration, distribution channel, and region.

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Diuretics

  • ACE Inhibitors

  • Calcium Channel Blockers

  • Beta-adrenergic Blockers

  • Vasodilators

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Primary Hypertension

  • Secondary Hypertension

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectables

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Retail Pharmacy

  • Hospital Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

  • U.S.

  • Canada

  • Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait